Obiettivo ChallengeUp to 40% of patients diagnosed with metastasised breast cancer fail to respond to treatment. Cancer cost the EU €126bn in 2009 incl. productivity losses of €42.6bn and lost working days worth €9.43bn. 3.2m citizens in EU lose their lives to cancer each year.SolutionCirculating Tumour Cells (CTC) are cells that have shed into the vasculature from a primary tumour and circulate in the bloodstream. CytoTrack has developed a breakthrough technology that can identify and isolate metastatic cancer cells from a blood sample. It is superior to all other technologies due to a very efficient and non-biased detection principle and an integrated feature to isolate individual cells for characterisation. It is the perfect tool to be used together with new single cell characterisation assays currently being introduced on the market.ImpactThe innovation will provide an effective, accurate, fast and cheap characterisation of CTCs in a single device, enabling pathologists and clinicians worldwide to deliver personalised medicine and cancer treatment targeted the exact mutation of the individual patient’s cancer form. CytoTrack expects that the innovation can reduce cancer deaths by 10%. In EU alone this would reduce the productivity loss with >€10bn per year and treatment costs with >€12.5bn.ProjectThis phase 1 project will investigate 1) collaboration with labs, 2) regulatory conditions for first markets, and 3) prepare for clinical trials. The overall innovation project will enable CytoTrack to be the first on the market to offer an integrated diagnostic platform for routine isolation and characterisation of metastatic cancer cells in blood, enabling personalised therapy targeting the exact profile of the cancer form.Customers and marketThe CTC technology market was $3.7bn in 2013, growing 18.9% annually. The research market is a first step in gaining a strong foothold before approaching the much larger, but also more challenging, clinical market. Campo scientifico social scienceseconomics and businesseconomicsproduction economicsproductivitymedical and health sciencesclinical medicineoncologybreast cancermedical and health sciencesclinical medicineoncologycolorectal cancernatural sciencesbiological sciencesgeneticsmutationmedical and health scienceshealth sciencespersonalized medicine Programma(i) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Argomento(i) PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Invito a presentare proposte H2020-SMEInst-2014-2015 Vedi altri progetti per questo bando Bando secondario H2020-SMEINST-1-2015 Meccanismo di finanziamento SME-1 - SME instrument phase 1 Coordinatore CYTOTRACK APS Contribution nette de l'UE € 50 000,00 Indirizzo GAMMEL LUNDTOFTEVEJ 1D 2800 Lyngby Danimarca Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Regione Danmark Hovedstaden Københavns omegn Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 71 429,00